Table 2 Comparison of the primary and secondary endpoints
Time to the resolution of symptoms | LHQW treatment group | Placebo group | HR (95%CI) | P value | ||
|---|---|---|---|---|---|---|
No. (%) of responders | Duration (days), Median (95% CI) | No. (%) of responders | Duration (days), Median (95% CI) | |||
Primary endpoint (Full-analysis set) | ||||||
 Nine major symptoms * | 356 (86.8%) | 4.0 (3.8–4.8) | 291 (71.9%) | 6.7 (5.9–7.9) | 1.63 (1.39–1.90) | < 0.001 |
Primary endpoint (Per-protocol set) | ||||||
 Nine major symptoms * | 349 (87.9%) | 4.0 (3.8–4.7) | 283 (73.1%) | 6.6 (5.8–7.7) | 1.64 (1.40–1.92) | < 0.001 |
Secondary endpoints (full-analysis set) | ||||||
 Stuffy or runny nose | 297 (94.9%) | 2.8 (2.3–3.0) | 278 (87.1%) | 3.7 (2.9–4.0) | 1.43 (1.21–1.69) | < 0.001 |
 Sore throat | 318 (96.4%) | 2.0 (1.9–2.4) | 309 (90.4%) | 2.6 (2.2–3.0) | 1.43 (1.22–1.67) | < 0.001 |
 Cough | 318 (90.1%) | 3.2 (2.9–3.7) | 259 (73.6%) | 4.9 (4.5–5.9) | 1.68 (1.43–1.99) | < 0.001 |
 Shortness of breath | 77 (95.1%) | 2.0 (1.1–2.8) | 81 (89.0%) | 2.7 (1.7–2.9) | 1.19 (0.87–1.62) | 0.279 |
 Low energy or tiredness | 237 (96.0%) | 1.3 (1.1–1.8) | 232 (91.7%) | 1.9 (1.7–2.2) | 1.40 (1.17–1.68) | < 0.001 |
 Myalgia | 216 (97.7%) | 1.5 (1.2–1.8) | 203 (92.3%) | 2.0 (1.6–2.2) | 1.40 (1.15–1.70) | < 0.001 |
 Headache | 194 (96.5%) | 1.4 (1.1–1.7) | 197 (95.6%) | 1.8 (1.4–1.9) | 1.15 (0.94–1.40) | 0.180 |
 Chills or shivering | 109 (97.3%) | 1.0 (0.9–1.3) | 109 (94.8%) | 1.3 (1.0–1.6) | 1.23 (0.95–1.61) | 0.120 |
 Feeling hot or feverish | 184 (97.9%) | 1.0 (1.0–1.3) | 188 (94.5%) | 1.3 (1.0–1.7) | 1.31 (1.07–1.60) | 0.010 |
 Normalized body temperature within 2 weeks | 80 (98.8%) | 1.0 (0.8–1.4) | 73 (98.6%) | 1.6 (1.3–1.9) | 1.37 (1.00–1.89) | 0.052 |